Hannah Norman-Bruce

Hannah Norman-Bruce

Auto-generated profile, based on publicly available information

Hannah Norman-Bruce

Queen's University Belfast, Belfast, UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2024 in The Lancet Child & Adolescent Health
Verified
Journal Article
Open access
HNHannah Norman-Bruce
Hannah Norman-Bruce
EUEtimbuk Umana
Etimbuk Umana
CMClare Mills
Clare Mills
HMHannah Mitchell
Hannah Mitchell
LMLisa McFetridge
Lisa McFetridge
TWThomas Waterfield
Thomas Waterfield
Febrile infants presenting in the first 90 days of life are at higher risk of invasive and serious bacterial infections than older children. Modern clinical practice guidelines, mostly using procalcitonin as a diagnostic biomarker, can identify infants who are at low risk and therefore suitable for tailored management. C-reactive protein, by comparison, is widely available, but whether C-reactive protein and procalcitonin have similar diagnostic accuracy is unclear. We aimed to compare the test accuracy of procalcitonin and C-reactive protein in the prediction of invasive or serious bacterial infections in febrile infants. For this systematic review and meta-analysis, we searched MEDLINE, EMBASE, Web of Science, and The Cochrane Library for diagnostic test accuracy studies up to June 19, 2023, using MeSH terms "procalcitonin", and "bacterial infection" or "fever" and keywords "invasive bacterial infection*" and "serious bacterial infection*", without language or date restrictions. Studies were selected by independent authors against eligibility criteria. Eligible studies included participants aged 90 days or younger presenting to hospital with a fever (≥38°C) or history of fever within the preceding 48 h. The primary index test was procalcitonin, and the secondary index test was C-reactive protein. Test kits had to be commercially available, and test samples had to be collected upon presentation to hospital. Invasive bacterial infection was defined as the presence of a bacterial pathogen in blood or cerebrospinal fluid, as detected by culture or quantitative PCR; authors' definitions of serious bacterial infection were used. Data were extracted from selected studies, and the detection of invasive or serious bacterial infections was analysed with two models for each biomarker. Diagnostic accuracy was determined against internationally recognised cutoff values (0·5 ng/mL for procalcitonin, 20 mg/L for C-reactive protein) and pooled to calculate partial area under the curve (pAUC) values for each biomarker. Optimum cutoff values were identified for each biomarker. This study is registered with PROSPERO, CRD42022293284. Of 734 studies derived from the literature search, 14 studies (n=7755) were included in the meta-analysis. For the detection of invasive bacterial infections, pAUC values were greater for procalcitonin (0·72, 95% CI 0·56-0·79) than C-reactive protein (0·28, 0·17-0·61; p=0·016). Optimal cutoffs for detecting invasive bacterial infections were 0·49 ng/mL for procalcitonin and 13·12 mg/L for C-reactive protein. For the detection of serious bacterial infections, procalcitonin and C-reactive protein had similar pAUC values (0·55, 0·44-0·69 vs 0·54, 0·40-0·61; p=0·92). For serious bacterial infections, the optimal cutoffs for procalcitonin and C-reactive protein were 0·17 ng/mL and 16·18 mg/L, respectively. Heterogeneity was low for studies investigating the test accuracy of procalcitonin in detecting invasive bacterial infection (I2=23·5%), high for studies investigating procalcitonin for serious bacterial infection (I2=75·5%), and moderate for studies investigating C-reactive protein for invasive bacterial infection (I2=49·5%) and serious bacterial infection (I2=28·3%). The absence of a single definition of serious bacterial infection across studies was the greatest source of interstudy variability and potential bias. Within a large cohort of febrile infants, a procalcitonin cutoff of 0·5 ng/mL had a superior pAUC value to a C-reactive protein cutoff of 20 mg/L for identifying invasive bacterial infections. In settings without access to procalcitonin, C-reactive protein should therefore be used cautiously for the identification of invasive bacterial infections, and a cutoff value below 20 mg/L should be considered. C-reactive protein and procalcitonin showed similar test accuracy for the identification of serious bacterial infection with internationally recognised cutoff values. This might reflect the challenges involved in confirming serious bacterial infection and the absence of a universally accepted definition of serious bacterial infection. None.

20 September 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
EUEtimbuk Umana
Etimbuk Umana
CMClare Mills
Clare Mills
HNHannah Norman-Bruce
Hannah Norman-Bruce
KWKathryn Wilson
Kathryn Wilson
HMHannah Mitchell
Hannah Mitchell
TWThomas Waterfield
Thomas Waterfield
Introduction Febrile infants 90 days and younger are at risk of invasive bacterial infections (bacteraemia and meningitis) and urinary tract infections. Together this is previously termed serious bacterial infection with an incidence of approximately 10–20%. The National Institute for Health and Care Excellence guidance advocates a cautious approach with most infants requiring septic screening, parenteral broad-spectrum antibiotics and hospital admission. Internationally, variations exist in the approach to febrile infants, with European and North American guidance advocating a tailored approach based on clinical features and biomarker testing. None of the available international clinical decision aids (CDAs) has been validated in the UK and Irish cohorts. The aim of the Febrile Infant Diagnostic Assessment and Outcome (FIDO) Study is to prospectively validate a range of CDAs in a UK and Irish population including CDAs that use procalcitonin testing. Methods and analysis The FIDO Study is a prospective multicentre mixed-methods cohort study conducted in UK and Irish hospitals. All infants aged 90 days and younger presenting with fever or history of fever (≥38°C) are eligible for inclusion. Infants will receive standard emergency clinical care without delay. Clinical data and blood samples will be collected, and consent will be obtained at the earliest appropriate opportunity using research without prior consent methodology. The performance and cost-effectiveness of CDAs will be assessed. An embedded qualitative study will explore clinician and caregiver views on different approaches to care and perceptions of risk. Ethics and dissemination This study was reviewed and approved by the Office for Research Ethics Committees Northern Ireland-Health and Social Care Research Ethics Committee B, Public Benefit and Privacy Panel for Health and Social Care Scotland, and Children’s Health Ireland Research and Ethics Committee Ireland. The results of this study will be presented at academic conferences and in peer-reviewed publications. Trial registration number NCT05259683.

4 October 2024 in BMJ Paediatrics Open
Verified
Journal Article
Open access
PDF file
JEJordan Evans
Jordan Evans
HNHannah Norman-Bruce
Hannah Norman-Bruce
CMClare Mills
Clare Mills
EUEtimbuk Umana
Etimbuk Umana
JRJennie Roe
Jennie Roe
TWThomas Waterfield
Thomas Waterfield
Introduction: Febrile infants under 3 months of age are at risk of invasive bacterial infection (IBI). It is currently unclear if testing for respiratory viruses may have a role in IBI risk stratification. If found to be associated with the likelihood of IBI, respiratory viral point-of-care testing may improve patient and caregiver experience, reduce costs and enhance antimicrobial stewardship.Methods and analysis: This is a study protocol for a systematic review and meta-analysis that aims to answer the following question:In young febrile infants presenting to emergency care settings does a positive respiratory viral test for RSV, Influenza or SARS-CoV2 (relative to a negative test) add value to current risk stratification pathways for the exclusion of invasive bacterial infection, subsequently enabling safe de-escalation of investigation and treatment?A search strategy will include MEDLINE, EMBASE, Web of Science, The Cochrane Library and grey literature. Abstracts and then full texts will be independently screened for selection. Data extraction and quality assessment will be completed by two independent authors.The primary objective is to analyse the ability of a positive respiratory viral test to identify the overall risk of IBI. The secondary objective is to perform a subgroup analysis to investigate how the risk stratification alters based on other variables including virus type, patient characteristics and the presence of an identified source of fever.Bivariate random-effects meta-analysis will be undertaken. Diagnostic odds ratios (OR), sensitivity, specificity and positive and negative likelihood ratios will be calculated. The degree of heterogeneity and publication bias will be investigated and presented.Ethics and dissemination: Ethical approval is not required. We will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to disseminate the study results through publication and conference presentations.PROSPERO registration number: This protocol is registered in PROSPERO—ID number: CRD42023433716.

25 August 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
HNHannah Norman-Bruce
Hannah Norman-Bruce
EUEtimbuk Umana
Etimbuk Umana
CMClare Mills
Clare Mills
LMLisa McFetridge
Lisa McFetridge
HMHannah Mitchell
Hannah Mitchell
TWThomas Waterfield
Thomas Waterfield
Introduction Young febrile infants are at higher risk of invasive bacterial infections (IBIs) compared with older children. The clinical features of IBI are subtle in this cohort mandating that clinicians take a cautious approach to their initial assessment and management. This includes the measurement of blood biomarkers of infection such as C reactive protein (CRP) and procalcitonin (PCT). In the UK, PCT is not widely available and not recommended for routine use in hospital. This is in contrast to Europe and the USA where PCT is regularly used to assist clinical decision-making. The objective of this review and meta-analysis is to report the diagnostic test accuracy of PCT in detecting IBI in febrile infants less than 91 days old, compare its accuracy with CRP and define optimal PCT cut-off values in this cohort. Methods and analysis A search strategy will include MEDLINE, EMBASE, Web of Science, The Cochrane Library and grey literature. There will be no language or date limitations. Diagnostic accuracy studies compliant with STARD criteria will be considered against eligibility criteria. Abstracts, then full texts, of potentially eligible studies will be independently screened for selection. Data extraction and quality assessment, using the QUADAS-2 tool, will be completed by two independent authors and a third author used for any inconsistencies. True positives, false positives, true negatives and false negatives will be pooled to collate specificity and sensitivity with 95% CIs. Results will be portrayed in forest plots, alongside their quality assessments. Ethics and dissemination This review does not require ethical clearance. This review will be published in peer-reviewed journals and key messages will be disseminated through presentations at local and international conferences related to this field. The authors aim for this review to be completed and published in 2023.

27 July 2026 in Exploration of Medicine
Verified
Journal Article
Open access
PDF file
HNHannah Norman-Bruce
Hannah Norman-Bruce
DMDavid J. McCleary
David J. McCleary
QGQi Sen Gan
Qi Sen Gan
HGHelen Elizabeth Groves
Helen Elizabeth Groves
TWThomas Waterfield
Thomas Waterfield
PMP. Jane McDowell
P. Jane McDowell
Acute wheeze is one of the most common paediatric presentations to emergency care. Although blood eosinophils (BEO) are an established biomarker of type 2 inflammation in stable asthma, their role in guiding acute management—particularly systemic corticosteroid use—remains unclear. The aim of this review was to map and synthesise the existing evidence on the measurement and clinical utility of BEO sampled during acute wheeze exacerbations in children. A scoping review was conducted in accordance with Joanna Briggs Institute methodology and Preferred Reporting Items for Systematic Reviews and Meta-Analysis extension for scoping reviews (PRISMA-ScR) guidelines. Medline, Embase, Cochrane Library and Web of Science were searched for studies published in the last 20 years involving children under 16 years presenting acutely with wheeze and undergoing eosinophil testing. Prospective and retrospective studies were included. Data were summarised descriptively according to eosinophil measurement methods, reported values, cut-offs and associations with characteristics and treatment response. Eight heterogeneous studies (n = 855) met inclusion criteria, comprising five observational or retrospective studies and three randomised controlled trials. BEO reporting varied widely, with inconsistent units, cut-offs and poorly described sampling timing. No study utilised point-of-care testing. Across studies, eosinophil dynamics differed by age, wheeze phenotype, disease severity and viral aetiology, preventing meaningful comparison. Evidence supporting eosinophil-guided corticosteroid use was limited. Two studies demonstrated improved outcomes with systemic corticosteroids in children with rhinovirus-associated wheeze and higher BEO, while lower BEO were observed in respiratory syncytial virus (RSV)-associated wheeze. There is a paucity of high-quality data describing BEO during acute wheeze exacerbations in children. Current evidence underpinning eosinophil-guided care is largely derived from stable outpatient cohorts and may not be directly applicable to acute settings. Prospective studies with standardised sampling of BEO during acute presentations are needed to inform precision-based corticosteroid use.

24 February 2026 in Pilot and Feasibility Studies
Verified
Journal Article
Open access
PDF file
HNHannah Norman–Bruce
Hannah Norman–Bruce
CMClare Mills
Clare Mills
HDHolly Drummond
Holly Drummond
KLKathy Li
Kathy Li
HMHannah Mitchell
Hannah Mitchell
HGHelen Groves
Helen Groves
Background: Wheezing in the pre-school aged group (under 5 years) is a common presentation and significant healthcare burden. It is a heterogenous presentation representing a spectrum of phenotypes, and although the causes may be multifactorial, viral infection is the most common trigger, with rhinovirus and Respiratory Syncytial Virus (RSV) being the most commonly detected. Rigorous evidence-based guidance for the acute management of preschool wheeze (PW) with respect to which children are likely to benefit from oral corticosteroid therapy (OCS) is lacking. RCTs of OCS use in PW have not adequately assessed the impact of respiratory virus testing in the management of PW. In order to address the hypothesis that OCS response may be determined by the specific virus in a future definitive trial, the feasibility of performing POC respiratory virus tests prior to randomisation in an acute paediatric ED setting needs to be ascertained. Methods: The PRECISE Study will be a single centre, randomised, open-label, feasibility trial. Children aged 24–59 months with acute wheeze will be eligible if the clinician is uncertain if there is a role for oral corticosteroid therapy or not. At enrolment, participants will undergo a nasal swab for rapid respiratory virus testing. Children will be randomised in a 1:1 ratio to receive oral dexamethasone or not, based on their RSV result. Participants will continue to be managed by the clinician according to local guidance. They will be invited for clinical review at 72 h where a repeat nasal swab may be performed. There will be a telephone follow-up at 1 month and parents will be invited for extended telephone interviews within a further month. Comprehensive screening logs will address the primary outcome of recruitment and timeliness until enrolment. Remaining timeliness and adherence outcomes will be recorded in individual participant records and described using CONSORT diagrams. Acceptability will be measured using both qualitative and quantitative approaches based on the theory of acceptability framework. Discussion: This pragmatically designed trial will address key feasibility points needed to inform a future, definitive multi-centre RCT prospectively testing the role of respiratory virus testing to randomise children with PW to receive oral corticosteroids or not. Trial registration: Clinicaltrials.gov ID NCT06580600.